United Therapeutics Corporation Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
United Therapeutics Corporation (UTHR) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $84.20 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-05
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $84.20M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $97.00M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $64.10M.
- 2025-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $73.30M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $84.20M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $97.00M 10-Q · filed 2026-05-06 |
| 2025-09-30 | $64.10M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $73.30M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $84.40M 10-Q · filed 2025-04-30 |
| 2024-09-30 | $62.00M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $68.00M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $75.90M 10-Q · filed 2024-05-01 |
| 2023-09-30 | $31.80M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $12.20M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $13.90M 10-Q · filed 2023-05-03 |
| 2022-09-30 | $11.90M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $15.70M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $21.30M 10-Q · filed 2022-05-04 |
| 2021-09-30 | $31.30M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $35.40M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $41.10M 10-Q · filed 2021-05-05 |
| 2016-09-30 | $44.10M 10-Q · filed 2016-10-27 |
| 2016-06-30 | $48.00M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $61.50M 10-Q · filed 2016-04-28 |
| 2015-12-31 | $5.40M 10-K · filed 2016-02-25 |
| 2014-12-31 | $0.00 10-K · filed 2016-02-25 |
| 2013-12-31 | $0.00 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |